San Diego-based bioTheranostics Inc., a provider of genomic cancer diagnostic solutions, said it signed a contract with FedMed Inc., based in Maryland and one of the largest preferred provider organizations in the nation.

The contract will provide FedMed’s 40 million members nationwide with access to bioTheranostics’ molecular diagnostic and predictive cancer tests including Breast Cancer Index, and the bioT3 Metastatic Cancer Solution.

Richard Ding, CEO of bioTheranostics, said the contract is one of a growing number of agreements the company has signed with national PPO networks, providing more than 130 million covered members with access to advanced molecular testing solutions for a more precise and personalized approach to managing cancer.